Diabetes Mellitus, Type 2
Conditions
Brief summary
Randomized, unblinded, controlled, two arms parallel group, prospective intervention study
Detailed description
The objective of the study is to compare the progression of HbA1c in diabetic patients after applying a Medwell digital application in addition to regular diabetes treatment (treatment arm) with regular diabetes treatment of diabetic subjects alone (control arm). The primary endpoint will be measured as the difference between 3 months HbA1c relative to baseline in eligible subjects. Normally, HbA1c in each subject is expected to either stable or slightly increase overtime. In this study we are interested in measuring the difference in HbA1c 3 months post randomization. It is expected that in the experimental arm, HbA1c will slightly decrease, while in the standard arm, HbA1c will either remain the same or will slightly increase after 3 months in the study. Previous study shows that the standard deviation of the difference in HbA1c within 1 year is 0.97%.
Interventions
DEVICEMedwell Preventive Care Application
Regular diabetes treatment with additional Medwell application and wearable device.
DEVICEManual Records
Regular diabetes treatment only with a diary card to record daily activities manually.
Sponsors
Immanuel Hospital
Prodia the CRO
PT Bio Farma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
This study is conducted with the primary hypothesis that the diabetes treatment with Medwell intervention can significantly reduce the HbA1c level better than without Medwell intervention.
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Subjects are in the diabetes type 2 status (based on Perkeni standard) HbA1c is ≥6.5% * Aged 18 - 60 years old * Have compatible smartphone (minimum android 8 or iOS 13) and internet connection * Receiving regular diabetes treatment * Giving consent and commitment to participate in the study until finish * Located in Bandung Area within the treatment period (up to 3 month after receiving the treatment) * Subject is determined to be able to complete daily physical activities.
Exclusion criteria
* Pregnant (based on test pack) * Participation in other weight loss program * Use of other tracking application * Having any abnormalities that affecting blood erythrocyte age defined by laboratory examination * Have other severe diabetic complications that prevent subjects from participating in the prescribed program (Such as stroke, cardiac diseases (CHF stage III-IV), COPD or asthma with acute exacerbation and other respiratory diseases, peripheral artery disease, CKD stage 3-5) and other severe diseases that by the investigator's judgment, could not participate in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HbA1C Changes | 3 months | Change in HbA1c from baseline to month 3 for all groups. Change in HbA1c from baseline to month 3 for all groups. Change in HbA1C from baseline to moth 3 of all group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Drug Adherence | 3 months | Proportion of administered drugs timely consumed by subjects |
| Anthropometry I (BMI) | 3 months | Change in the BMI after 3 months |
| Anthropometry II (Body Fat) | 3 months | Change in the Body Fat after 3 months |
| Anthropometry III (Muscle Mass) | 3 months | Change in the Muscle Mass after 3 months |
| Lab outcome I (Fasting glucose) | 3 months | Change in the lab measurement from baseline to month 3 for fasting glucose |
| Evaluate the exercise | 3 months | Mean weekly frequency of exercise |
| Lab outcome III (total cholesterol) | 3 months | Change in the lab measurement from baseline to month 3 for total cholesterol |
| Lab outcome IV (low density lipoprotein) | 3 months | Change in the lab measurement from baseline to month 3 for low density lipoprotein |
| Lab outcome V (high density lipoprotein) | 3 months | Change in the lab measurement from baseline to month 3 for high density lipoprotein |
| Lab outcome VI (triglyceride) | 3 months | Change in the lab measurement from baseline to month 3 for triglyceride |
| Lab outcome II (2 hours post prandial glucose) | 3 months | Change in the lab measurement from baseline to month 3 for 2 hours postprandial glucose |
Countries
Indonesia
Contacts
Primary ContactAsep Irham, MD
Backup ContactSalwa Halimatussadiy
Outcome results
None listed